Thr546
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr546  -  Caldesmon (human)

Site Information
LRRRRGEtEsEEFEK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 7824171
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 3 , 4 , 5 ) , non-small cell lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 ) , non-small cell squamous cell lung carcinoma ( 5 ) , melanoma skin cancer ( 2 , 7 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 4 ) , breast ( 1 ) , HCC15 (pulmonary) ( 5 ) , HeLa (cervical) ( 8 ) , LOU-NH91 (squamous) ( 5 ) , lung ( 4 , 5 ) , NCI-H1355 (pulmonary) ( 4 ) , NCI-H1703 (squamous) ( 5 ) , NCI-H1792 (pulmonary) ( 4 ) , NCI-H2073 (pulmonary) ( 5 ) , NCI-H23 (pulmonary) ( 4 ) , NCI-H2342 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 4 ) , PC9 (pulmonary) ( 3 ) , PC9-IR (pulmonary) ( 3 ) , skin ( 7 ) , WM239A (epidermal) ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

7

Tucker M (2008) CST Curation Set: 5369; Year: 2008; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

8

McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80
18212344   Curated Info